• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Lucence, Carbon Health tout COVID-19 test kits

Lucence, Carbon Health tout COVID-19 test kits

March 20, 2020 By Nancy Crotti

(Image from Lucence)

Singapore-based Lucence said it has developed a sample collection device for viral infections such as COVID-19.

Unlike other companies’ tests, Lucence’s SAFER-Sample  (Stabilization of nucleic Acid Formulation for Evaluation of RNA) does not require samples from nose or throat swabs to be chilled for transport to a lab, according to the company.

It comes with a bottle of stabilization fluid to be mixed with the sample at the point of collection, keeping viral RNA stable at room temperature for up to one week, according to Lucence. The sample can then be transported to a testing lab without the need for chilling, especially useful in countries where samples must be transported long distances for testing.

“We are very glad that our technology, used to reduce suffering of cancer patients, can contribute to accurate testing solutions during this global crisis,” said Lucence CEO Dr. Tan Min-Han in a news release. “In line with our mission of using molecular technology to improve health worldwide, we are making up to 10,000 kits available at no cost to the scientific community.”

Separately, San Francisco-based Carbon Health announced today that it is shipping COVID-19 home test kits to California patients who feel sick and whose providers recommend they stay at home. (California Gov. Gavin Newsom yesterday ordered all Californians to stay home to reduce the spread of the disease.) The tests are currently available to patients located in California for an at-cost fee of $167.50. Carbon Health plans to offer them nationwide, pending state regulations.

Carbon Health said in a news release that digital pharmacy Alto Pharmacy, also in San Francisco will to deliver the test kits and that an unnamed medical device manufacturer developed the kit and will provide laboratory testing.

“Between supply shortages and lack of capacity, testing for COVID-19 is one of our country’s biggest obstacles to containing the outbreak,” said Carbon Health CEO Eren Bali in a news release. “Our proprietary technology and partnership with Alto Pharmacy allowed us to move fast and efficiently create, analyze and distribute testing. We are also looking for more partners as we expand our distribution of home test kits. Our goal is to keep moving forward and make these tests widely accessible so that patients and clinicians everywhere benefit as quickly as possible.”

Filed Under: Business/Financial News, Diagnostics, Featured, Genomics/Molecular Diagnostics Tagged With: Alto Pharmacy, Carbon Health, coronavirus, Lucence

More recent news

  • Tandem continues to deliver more options, benefits for those with diabetes
  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Endogenex data supports type 2 diabetes procedure

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy